Literature DB >> 2789275

Hypocholesterolemia in patients treated with recombinant interleukin-2: appearance of remnant-like lipoproteins.

D E Wilson1, G R Birchfield, J S Hejazi, J H Ward, W E Samlowski.   

Abstract

Reversible acute hypocholesterolemia was observed during treatment of metastatic cancer with high-dose intravenous recombinant interleukin-2 (IL-2). Further analysis revealed virtual disappearance of high-density lipoproteins (HDLs) and marked reduction in the concentration of low-density lipoproteins (LDL); the remaining LDL and intermediate-density lipoproteins (IDL) were enriched in triglyceride relative to cholesterol and had broad-beta electrophoretic mobility, properties reminiscent of remnant lipoproteins. These changes differ qualitatively and quantitatively from those previously reported for other cytokines such as tumor necrosis factor (TNF) or the interferons (IFNs).

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2789275     DOI： 10.1200/JCO.1989.7.10.1573

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


  6 in total

Review 1.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

2.  Increased hepatic cholesterol accumulation in transgenic mice overexpressing human secretory phospholipase A2 group IIA.

Authors:  Rolf Eckey; Mario Menschikowski; Peter Lattke; Werner Jaross
Journal:  Inflammation       Date:  2004-04       Impact factor: 4.092

3.  Association of lipid accumulation in small intestinal mucosa with decreased serum triglyceride and cholesterol levels in AIDS.

Authors:  Y Benhamou; I Hilmarsdottir; I Desportes-Livage; C Hoang; A Datry; M Danis; M Gentilini; P Opolon
Journal:  Dig Dis Sci       Date:  1994-10       Impact factor: 3.199

Review 4.  Clinical toxicity of interleukin-2.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

5.  Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.

Authors:  P Lissoni; F Brivio; S Pittalis; M S Perego; A Ardizzoia; O Mauri; S Barni; S Crispino; G Tancini
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

6.  Human T-lymphotropic virus type-I infection, antibody titers and cause-specific mortality among atomic-bomb survivors.

Authors:  K Arisawa; M Soda; M Akahoshi; T Matsuo; E Nakashima; M Tomonaga; H Saito
Journal:  Jpn J Cancer Res       Date:  1998-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.